Telaprevir Ups Response Rates Across IL28B Genotypes in Hepatitis C
May 12, 2011|Family Medicine
Author and Disclosure Information
FROM THE ANNUAL DIGESTIVE DISEASE WEEK
Further research, including studies on nonwhites, is needed to confirm these findings, Dr. Jacobson said.
Dr. Jacobson disclosed numerous financial relationships with industry including grant support and other financial benefits from Tibotec and Vertex Pharmaceuticals, which are developing telaprevir together. Several coauthors also disclosed financial relationships including employment with Vertex.
